FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380367097> ?p ?o ?g. }

• W4380367097 endingPage "82" @default.
• W4380367097 startingPage "81" @default.
• W4380367097 abstract "Background: Bleeding complications remain common in extracorporeal membrane oxygenation (ECMO) and can be associated with adverse outcomes. Effect of excessive shear stress on vasculature may increase bleeding risk associated with preferential loss of high molecular weight von Willebrand factor (high molecular weight (vWF) multimers; acquired vW syndrome, AVWS) and may also be associated with platelet dysfunction. Some pediatric patients may have a pre-existing increased risk of shear-related abnormalities which may further increase bleeding risk on ECMO. We aimed to review bleeding events requiring intervention in a pediatric ECMO cohort. Methods: Retrospective review of pediatric ECMO patients who underwent treatment of bleeding beyond simple transfusion in conjunction with ECMO anticoagulation consultation (EAC) between June 2020 and December 2022 was conducted. Results: Fifty patients required ECMO for 53 runs (52 VA, 2 VV, 1 VAV). Median weight was 4.3 kg (2.4-131 kg). Mean duration of ECMO was 11 days (2-97). 60% (30/50) of patients had congenital heart disease (CHD), and within these 30 patients, 27% of them had bleeding requiring procedural intervention. Ten patients with bleeding were screened for AVWS guided by EAC with 100% meeting criteria for AVWS. Platelet transfusions were administered as first line bleeding therapy with thrombocytopenia or platelet dysfunction and plasma or prothrombin complex concentrate (PCCC) in volume-sensitive patients for coagulopathy. With ongoing bleeding despite transfusion, antihemophilic factor/vWF complex (Humate P) was administered to 4 patients guided by EAC (figure 1). Of these 4 patients, 75% had CHD and 100% had valve abnormalities with 50% having new mechanical valves placed within 1 month prior to ECMO. Initial Humate P dose was given on mean day 14, with mean number of 8 doses. No circuit or mechanical valve thrombosis occurred. Platelet counts and function improved with a decrease in platelet transfusions and clinical bleeding in all patients following Humate P. Conclusion: Bleeding remains a common complication but is often multifactorial and may be difficult to determine specific etiologies. AVWS and thrombocytopenia commonly occur during pediatric ECMO. However, not all patients have clinical bleeding, such that additional risk factors may contribute to increased bleeding risk in these patients. Given impact of recurrent transfusions due to bleeding on morbidity and mortality, as well as cost consideration and potential thrombosis risk of vWF or PCCC supplementation, development of an expert-guided (EAC) algorithm for screening and treatment criteria for such agents appears to be safe, cost-effective and may be associated with decreased bleeding and transfusions. Further research into etiologies and consequences of ECMO-induced bleeding as well as treatment is needed.Figure 1. Algorithm for Assessment of Persistent Bleeding and Consideration of Humate P Administration (pilot)." @default.
• W4380367097 created "2023-06-13" @default.
• W4380367097 creator A5000807491 @default.
• W4380367097 creator A5005419786 @default.
• W4380367097 creator A5009974653 @default.
• W4380367097 creator A5011156128 @default.
• W4380367097 creator A5020224376 @default.
• W4380367097 creator A5022095208 @default.
• W4380367097 creator A5026999672 @default.
• W4380367097 creator A5029316300 @default.
• W4380367097 creator A5036917439 @default.
• W4380367097 creator A5038475478 @default.
• W4380367097 creator A5047496504 @default.
• W4380367097 creator A5057065061 @default.
• W4380367097 creator A5069342537 @default.
• W4380367097 creator A5085530995 @default.
• W4380367097 creator A5086748152 @default.
• W4380367097 creator A5087139036 @default.
• W4380367097 date "2023-06-01" @default.
• W4380367097 modified "2023-10-16" @default.
• W4380367097 title "PEDS9: Bleeding in Pediatric Patients on Extracorporeal Membrane Oxygenation-Use of Procoagulant Factors" @default.
• W4380367097 doi "https://doi.org/10.1097/01.mat.0000943692.58094.d3" @default.
• W4380367097 hasPublicationYear "2023" @default.
• W4380367097 type Work @default.
• W4380367097 citedByCount "0" @default.
• W4380367097 crossrefType "journal-article" @default.
• W4380367097 hasAuthorship W4380367097A5000807491 @default.
• W4380367097 hasAuthorship W4380367097A5005419786 @default.
• W4380367097 hasAuthorship W4380367097A5009974653 @default.
• W4380367097 hasAuthorship W4380367097A5011156128 @default.
• W4380367097 hasAuthorship W4380367097A5020224376 @default.
• W4380367097 hasAuthorship W4380367097A5022095208 @default.
• W4380367097 hasAuthorship W4380367097A5026999672 @default.
• W4380367097 hasAuthorship W4380367097A5029316300 @default.
• W4380367097 hasAuthorship W4380367097A5036917439 @default.
• W4380367097 hasAuthorship W4380367097A5038475478 @default.
• W4380367097 hasAuthorship W4380367097A5047496504 @default.
• W4380367097 hasAuthorship W4380367097A5057065061 @default.
• W4380367097 hasAuthorship W4380367097A5069342537 @default.
• W4380367097 hasAuthorship W4380367097A5085530995 @default.
• W4380367097 hasAuthorship W4380367097A5086748152 @default.
• W4380367097 hasAuthorship W4380367097A5087139036 @default.
• W4380367097 hasBestOaLocation W43803670971 @default.
• W4380367097 hasConcept C126322002 @default.
• W4380367097 hasConcept C141071460 @default.
• W4380367097 hasConcept C167135981 @default.
• W4380367097 hasConcept C2776301958 @default.
• W4380367097 hasConcept C2776858399 @default.
• W4380367097 hasConcept C2777091921 @default.
• W4380367097 hasConcept C2778780528 @default.
• W4380367097 hasConcept C2779161974 @default.
• W4380367097 hasConcept C2779394231 @default.
• W4380367097 hasConcept C2779936836 @default.
• W4380367097 hasConcept C42219234 @default.
• W4380367097 hasConcept C71924100 @default.
• W4380367097 hasConcept C89560881 @default.
• W4380367097 hasConceptScore W4380367097C126322002 @default.
• W4380367097 hasConceptScore W4380367097C141071460 @default.
• W4380367097 hasConceptScore W4380367097C167135981 @default.
• W4380367097 hasConceptScore W4380367097C2776301958 @default.
• W4380367097 hasConceptScore W4380367097C2776858399 @default.
• W4380367097 hasConceptScore W4380367097C2777091921 @default.
• W4380367097 hasConceptScore W4380367097C2778780528 @default.
• W4380367097 hasConceptScore W4380367097C2779161974 @default.
• W4380367097 hasConceptScore W4380367097C2779394231 @default.
• W4380367097 hasConceptScore W4380367097C2779936836 @default.
• W4380367097 hasConceptScore W4380367097C42219234 @default.
• W4380367097 hasConceptScore W4380367097C71924100 @default.
• W4380367097 hasConceptScore W4380367097C89560881 @default.
• W4380367097 hasIssue "Supplement 2" @default.
• W4380367097 hasLocation W43803670971 @default.
• W4380367097 hasLocation W43803670972 @default.
• W4380367097 hasOpenAccess W4380367097 @default.
• W4380367097 hasPrimaryLocation W43803670971 @default.
• W4380367097 hasRelatedWork W184289008 @default.
• W4380367097 hasRelatedWork W1914090303 @default.
• W4380367097 hasRelatedWork W1975678986 @default.
• W4380367097 hasRelatedWork W2021431102 @default.
• W4380367097 hasRelatedWork W2083190218 @default.
• W4380367097 hasRelatedWork W2094037791 @default.
• W4380367097 hasRelatedWork W2511874891 @default.
• W4380367097 hasRelatedWork W3111849193 @default.
• W4380367097 hasRelatedWork W4225365101 @default.
• W4380367097 hasRelatedWork W4380367097 @default.
• W4380367097 hasVolume "69" @default.
• W4380367097 isParatext "false" @default.
• W4380367097 isRetracted "false" @default.
• W4380367097 workType "article" @default.